Cardiac controlled release for arrhythmia therapy: Lidocaine-polyurethane matrix studies

Amnon Sintov, William Scott, Macdonald Dick, Robert J. Levy

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Cardiac arrhythmias are the principal cause of sudden death due to heart disease, and current therapy is inadequate. A novel approach for formulating a lidocaine-polyurethane controlled release matrix and implanting this drug delivery system directly onto the arrhythmic epicardium is reported. Lidocaine-HCl-polyurethane matrices (28% w/w) were fabricated and studied for their in vitro drug release into physiologic buffer, and their in vivo pharmacologie effectiveness in rapidly converting ouabain-induced ventricular tachycardia in dogs to normal sinus rhythm. In vitro lidocaine release was successfully modulated as a result of variations in fabrication: compression molding, and stirring during polymer synthesis. Lidocaine release in vitro from the most rapidly releasing matrix formulation delivered more than 40% of the contained drug delivered after only 20 minutes, and the remainder slowly released over one week or more. Direct epimyocardial placement of this formulation resulted in the prompt conversion of ouabain-induced ventricular tachycardia to normal sinus rhythm in all experimental animals (n = 6) studied in 1.5 ± 0.77 min (mean ± standard error), while controls (n = 4) had persistent ventricular tachycardia for more than 60 min. Site-specific therapy was as rapid as intravenous administration, but with lower plasma lidocaine levels after comparable dosages. It is concluded that lidocaine-polyurethane controlled release matrices can be fabricated with a broad range of initial release profiles, and that these matrices can rapidly initiate the conversion of ouabain-induced ventricular tachycardia to normal sinus rhythm.

Original languageEnglish (US)
Pages (from-to)157-165
Number of pages9
JournalJournal of Controlled Release
Volume8
Issue number2
DOIs
StatePublished - 1988

Fingerprint

Polyurethanes
Lidocaine
Cardiac Arrhythmias
Ventricular Tachycardia
Ouabain
Therapeutics
Pericardium
Drug Delivery Systems
Sudden Death
Intravenous Administration
Cause of Death
Heart Diseases
Buffers
Polymers
Dogs
Pharmaceutical Preparations
In Vitro Techniques

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Cardiac controlled release for arrhythmia therapy : Lidocaine-polyurethane matrix studies. / Sintov, Amnon; Scott, William; Dick, Macdonald; Levy, Robert J.

In: Journal of Controlled Release, Vol. 8, No. 2, 1988, p. 157-165.

Research output: Contribution to journalArticle

Sintov, Amnon ; Scott, William ; Dick, Macdonald ; Levy, Robert J. / Cardiac controlled release for arrhythmia therapy : Lidocaine-polyurethane matrix studies. In: Journal of Controlled Release. 1988 ; Vol. 8, No. 2. pp. 157-165.
@article{01d2dd8e2d0a431ab0256dcfd230adf1,
title = "Cardiac controlled release for arrhythmia therapy: Lidocaine-polyurethane matrix studies",
abstract = "Cardiac arrhythmias are the principal cause of sudden death due to heart disease, and current therapy is inadequate. A novel approach for formulating a lidocaine-polyurethane controlled release matrix and implanting this drug delivery system directly onto the arrhythmic epicardium is reported. Lidocaine-HCl-polyurethane matrices (28{\%} w/w) were fabricated and studied for their in vitro drug release into physiologic buffer, and their in vivo pharmacologie effectiveness in rapidly converting ouabain-induced ventricular tachycardia in dogs to normal sinus rhythm. In vitro lidocaine release was successfully modulated as a result of variations in fabrication: compression molding, and stirring during polymer synthesis. Lidocaine release in vitro from the most rapidly releasing matrix formulation delivered more than 40{\%} of the contained drug delivered after only 20 minutes, and the remainder slowly released over one week or more. Direct epimyocardial placement of this formulation resulted in the prompt conversion of ouabain-induced ventricular tachycardia to normal sinus rhythm in all experimental animals (n = 6) studied in 1.5 ± 0.77 min (mean ± standard error), while controls (n = 4) had persistent ventricular tachycardia for more than 60 min. Site-specific therapy was as rapid as intravenous administration, but with lower plasma lidocaine levels after comparable dosages. It is concluded that lidocaine-polyurethane controlled release matrices can be fabricated with a broad range of initial release profiles, and that these matrices can rapidly initiate the conversion of ouabain-induced ventricular tachycardia to normal sinus rhythm.",
author = "Amnon Sintov and William Scott and Macdonald Dick and Levy, {Robert J.}",
year = "1988",
doi = "10.1016/0168-3659(88)90042-9",
language = "English (US)",
volume = "8",
pages = "157--165",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Cardiac controlled release for arrhythmia therapy

T2 - Lidocaine-polyurethane matrix studies

AU - Sintov, Amnon

AU - Scott, William

AU - Dick, Macdonald

AU - Levy, Robert J.

PY - 1988

Y1 - 1988

N2 - Cardiac arrhythmias are the principal cause of sudden death due to heart disease, and current therapy is inadequate. A novel approach for formulating a lidocaine-polyurethane controlled release matrix and implanting this drug delivery system directly onto the arrhythmic epicardium is reported. Lidocaine-HCl-polyurethane matrices (28% w/w) were fabricated and studied for their in vitro drug release into physiologic buffer, and their in vivo pharmacologie effectiveness in rapidly converting ouabain-induced ventricular tachycardia in dogs to normal sinus rhythm. In vitro lidocaine release was successfully modulated as a result of variations in fabrication: compression molding, and stirring during polymer synthesis. Lidocaine release in vitro from the most rapidly releasing matrix formulation delivered more than 40% of the contained drug delivered after only 20 minutes, and the remainder slowly released over one week or more. Direct epimyocardial placement of this formulation resulted in the prompt conversion of ouabain-induced ventricular tachycardia to normal sinus rhythm in all experimental animals (n = 6) studied in 1.5 ± 0.77 min (mean ± standard error), while controls (n = 4) had persistent ventricular tachycardia for more than 60 min. Site-specific therapy was as rapid as intravenous administration, but with lower plasma lidocaine levels after comparable dosages. It is concluded that lidocaine-polyurethane controlled release matrices can be fabricated with a broad range of initial release profiles, and that these matrices can rapidly initiate the conversion of ouabain-induced ventricular tachycardia to normal sinus rhythm.

AB - Cardiac arrhythmias are the principal cause of sudden death due to heart disease, and current therapy is inadequate. A novel approach for formulating a lidocaine-polyurethane controlled release matrix and implanting this drug delivery system directly onto the arrhythmic epicardium is reported. Lidocaine-HCl-polyurethane matrices (28% w/w) were fabricated and studied for their in vitro drug release into physiologic buffer, and their in vivo pharmacologie effectiveness in rapidly converting ouabain-induced ventricular tachycardia in dogs to normal sinus rhythm. In vitro lidocaine release was successfully modulated as a result of variations in fabrication: compression molding, and stirring during polymer synthesis. Lidocaine release in vitro from the most rapidly releasing matrix formulation delivered more than 40% of the contained drug delivered after only 20 minutes, and the remainder slowly released over one week or more. Direct epimyocardial placement of this formulation resulted in the prompt conversion of ouabain-induced ventricular tachycardia to normal sinus rhythm in all experimental animals (n = 6) studied in 1.5 ± 0.77 min (mean ± standard error), while controls (n = 4) had persistent ventricular tachycardia for more than 60 min. Site-specific therapy was as rapid as intravenous administration, but with lower plasma lidocaine levels after comparable dosages. It is concluded that lidocaine-polyurethane controlled release matrices can be fabricated with a broad range of initial release profiles, and that these matrices can rapidly initiate the conversion of ouabain-induced ventricular tachycardia to normal sinus rhythm.

UR - http://www.scopus.com/inward/record.url?scp=0024246861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024246861&partnerID=8YFLogxK

U2 - 10.1016/0168-3659(88)90042-9

DO - 10.1016/0168-3659(88)90042-9

M3 - Article

AN - SCOPUS:0024246861

VL - 8

SP - 157

EP - 165

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 2

ER -